Finance

Lists
Why is CRL up 5,14%?
Dive Deeper
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
USD 315,45
+5,14%
(+15,43) 1D
USD 315,45
0,00% (0,00)
After hours
Closed: 20 Okt., 16:00:07 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
USD 308,84
High
USD 317,59
Low
USD 304,00
Mkt. cap
15,06 mjd
Avg. vol.
971,54 k
Volume
1,27 m
52-wk high
USD 333,30
52-wk low
USD 146,20
EPS
-USD 4,85
Beta
1,40
Shares outstanding
47,74 m
No. of employees
19 k
Open
USD 308,84
High
USD 317,59
Low
USD 304,00
Mkt. cap
15,06 mjd
Avg. vol.
971,54 k
Volume
1,27 m
52-wk high
USD 333,30
52-wk low
USD 146,20
EPS
-USD 4,85
Beta
1,40
Shares outstanding
47,74 m
No. of employees
19 k
News stories
From web sources and news partners
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees19 k
Founded1947
HeadquartersWilmington, Massachusetts, Verenigde State van Amerika
SectorHealth care
Websitecriver.com
Analyst ratings
Based on 15 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
14
Hold
1
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current USD 315,45
USD 357,00 (+13,17%)
Average
USD 329,85 (+4,56%)
Lowest
USD 295,00 (-6,48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Casey Woodring
J.P. Morgan
Buy
Maintained
USD 345,00
+9,4%
10/16/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
USD 340,00
+7,8%
10/13/2026
Ryan Halsted
RBC Capital
Buy
Maintained
USD 322,00
+2,1%
10/06/2026
Kevin Caliendo
UBS
Buy
Initiated
USD 357,00
+13,2%
09/30/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
USD 340,00
+7,8%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
USD 320,00
+1,4%
09/25/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
USD 330,00
+4,6%
09/25/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
USD 295,00
-6,5%
09/25/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
USD 334,00
+5,9%
09/25/2026
Luke Sergott
Barclays
Buy
Maintained
USD 330,00
+4,6%
09/24/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
USD 325,00
+3%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
USD 320,00
+1,4%
09/22/2026
David Toung
Argus Research
Buy
Reiterated
USD 330,00
+4,6%
09/16/2026
Michael Luo CFA
CLSA
Hold
Downgraded
USD 219,00
-30,6%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
USD 265,00
-16%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
USD 215,00
-31,8%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
USD 175,00
-44,5%
02/25/2026
Last report
05 Aug. 2026
Fiscal period
Q2 2026
USD 3,02 / USD 2,74
+10,31%beat
Revenue / Est. (USD)
1,00 mjd / 977,20 m
+2,75%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,00 mjd
994,23 m
995,83 m
1,00 mjd
Cost of goods sold
652,72 m
665,36 m
672,79 m
625,06 m
Cost of revenue
652,72 m
665,36 m
672,79 m
625,06 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
173,64 m
192,02 m
149,12 m
214,18 m
Operating expense
201,05 m
284,04 m
164,46 m
227,27 m
Total operating expenses
853,77 m
949,40 m
837,25 m
852,33 m
Operating income
151,08 m
44,83 m
158,58 m
151,74 m
Other non operating income
-22,62 m
27,72 m
-123,11 m
25,99 m
EBT including unusual items
87,20 m
-294,10 m
-29,94 m
53,17 m
EBT excluding unusual items
104,48 m
35,18 m
8,62 m
148,43 m
Income tax expense
31,64 m
-17,81 m
-15,14 m
53,93 m
Effective tax rate
36,29%
6,06%
50,56%
101,43%
Other operating expenses
-
-
-
-
Net income
54,42 m
-276,56 m
-14,84 m
-1,48 m
Net profit margin
5,42%
-27,82%
-1,49%
-0,15%
Earnings per share
2,43
2,39
2,06
3,02
Interest and investment income
1,42 m
1,02 m
1,03 m
1,03 m
Interest expense
-25,40 m
-23,78 m
-26,74 m
-30,34 m
Net interest expenses
-23,98 m
-22,76 m
-25,71 m
-29,31 m
Depreciation and amortization charges
-
-
-
-
EBITDA
236,25 m
169,61 m
225,73 m
217,54 m
Gain or loss from assets sale
-
-
117,98 m
24,92 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme